Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients

Illa, Isabel; Díaz-Manera, Jordi; Rojas‐García, Ricard; Pradas, Jesús; Rey, Antonio; Blesa, Rafael; Júarez, Cándido; Gallardo, Eduard

doi:10.1016/j.jneuroim.2008.04.039

Cited by 122 publications

(94 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in agreement with previous reports of its efficacy. [5][6][7]9 The need for treatments for patients who do not respond to traditional therapy has led to a search for new options. Rituximab is an appealing treatment choice due to its mechanism of action targeting CD20…”

Section: Discussionmentioning

confidence: 99%

Rituximab in the management of refractory myasthenia gravis

et al. 2009

View full text Add to dashboard Cite

Myasthenia gravis (MG) is an immune-mediated disorder with a variable response to treatment. In this study, patients with refractory MG who were treated with rituximab were identified. A review of patients referred to the Yale Neuromuscular Clinic was performed. Patients with refractory MG who were treated with rituximab were reviewed for response to treatment. Patients who had muscle-specific kinase (MuSK(+)) or acetylcholine receptor (AChR(+)) antibodies were included. Six patients were identified who met the criteria described. All patients tolerated rituximab without side effects and had a reduced need for immunosuppressants and/or improvement in clinical function. Patients with refractory MG appeared to respond to rituximab in this small, retrospective study. This result suggests that a larger, prospective trial is indicated.

show abstract

Section: Discussionmentioning

confidence: 99%

Rituximab in the management of refractory myasthenia gravis

et al. 2009

View full text Add to dashboard Cite

show abstract

“…In the search of an efficacious and safe drug for "refractory" MG, several authors have reported encouraging experience with rituximab [4][5][6][7][8][9][10][11][12]. Rituximab is a monoclonal antibody directed against the CD20 antigen of B cells and their precursors.…”

Section: Introductionmentioning

confidence: 99%

Rituximab for myasthenia gravis

Stieglbauer

Topakian

Schäffer

et al. 2009

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…This case report illustrates the favorable profile of efficacy and safety of rituximab for the treatment of refractory MG, as others authors have already shown [6][7][8][9][10]. Unfortunately, there is no prospective randomized trial with rituximab in this scenario, which prevents a formal recommendation and precludes its use in larger scale [12].…”

mentioning

confidence: 68%

“…Its effectiveness in the treatment of myasthenia gravis has been demonstrated in case reports and cases series since the last decade [6][7][8][9][10]. It may be used with prednisone, and adverse effects are rare, but potentially serious events, such as increased incidence of infections, progressive multifocal leukoencephalopathy and allergic reactions have been reported [2].…”

Section: Introductionmentioning

confidence: 99%

Treating Refractory Myasthenia Gravis with Rituximab – Case Report

Rmp¹,

Fq²,

Mvg³

et al. 2017

Journal of Neurology and Neurological Disorders

View full text Add to dashboard Cite

Myasthenia gravis is an autoimmune disease characterized by motor plaque dysfunction due to antibodies against post-synaptic membrane proteins. Myasthenic symptoms classically wax and wane and are more intense at the end of the day, although they may be constant in severe pictures. Almost every patient have eyelid ptosis and double vision, and the majority of them also have proximal muscle weakness. Reversible cholinesterase inhibitors are the first-line treatment, but patients who do not achieve symptom control should receive immunosuppressive therapy, whose options include azathioprine, cyclosporine, mycophenolate, intravenous immunoglobulin and thymectomy, with different profiles of efficacy, safety and tolerability. For more than a decade, rituximab, an immunobiological agent directed against B lymphocytes, has been shown to be effective in case reports and series of cases of refractory myasthenic patients, showing few side effects. We report the case of a patient with an excellent response to 3 infusions of rituximab with intervals between 9 and 12 months between each.

show abstract

Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients

Cited by 122 publications

References 36 publications

Rituximab in the management of refractory myasthenia gravis

Rituximab in the management of refractory myasthenia gravis

Rituximab for myasthenia gravis

Treating Refractory Myasthenia Gravis with Rituximab – Case Report

Contact Info

Product

Resources

About